Aviva
AUPH icon

Aviva’s Aurinia Pharmaceuticals AUPH Stock Holding History

Aviva’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450K Sell
26,527
-4,640
-15% -$74.1K ﹤0.01% 757
2026
Q1 		$462K Sell
31,167
-677
-2% -$9.89K ﹤0.01% 717
2025
Q4 		$508K Sell
31,844
-6,832
-18% -$96.8K ﹤0.01% 739
2025
Q3 		$427K Buy
+38,676
New +$422K ﹤0.01% 842

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aviva's AUPH Position: Q2 2026 in Review

Aviva reduced its Aurinia Pharmaceuticals (AUPH) stake by 15% in Q2 2026, selling an estimated $74.1K and leaving 26,527 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #757.

Aviva first reported a position in AUPH in Q3 2025 and has held it in 4 quarters since. The position peaked at $508K in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Aviva held 26,527 shares of Aurinia Pharmaceuticals worth $450K as of Q2 2026.
  • Aviva sold 4,640 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $74.1K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #757 holding.
  • Aviva first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Aviva's Aurinia Pharmaceuticals position peaked at $508K in Q4 2025.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.